ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KYTX vs FENC // OPERATING MARGIN

Kyverna Therapeutics Inc. (NASDAQ) VS. Fennec Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KYTX 1 — FENC 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYTX VS. FENC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KYTX FENC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -25.90% -9.10 FENC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -3.25% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -14.10% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -6.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.31 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 KYTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.8 46.3 -4.50 FENC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $350.7M $358.7M -$8.1M FENC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KYTX REV FENC REV KYTX GROSS % FENC GROSS % KYTX FCF FENC FCF
FY 2025 $475.5M $44.6M — — -$153.7M -$12.5M
FY 2024 $399.3M $47.5M — — -$116.5M $27.0M
FY 2023 $174.7M $21.3M — — -$52.4M -$17.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYTX // BETA —
FENC // BETA —